News
Eli Lilly (LLY) made headlines with positive results from the Phase 3 BRUIN CLL-314 clinical trial for Jaypirca, marking a significant advancement in treatment options for chronic lymphocytic leukemia ...
Novo Nordisk stocks plunged by 7% in premarket trading following an announcement by the company that it has lowered its ...
Asianet Newsable on MSN30m
Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The StockJaypirca had an overall response rate better than AbbVie’s Imbruvica in the study, meaning a higher percentage of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback